Bruker Reports 17.4% Revenue Growth in Q2 2024
Bruker sees strong growth in Q2 2024, with strategic acquisitions boosting revenues despite challenges in biopharma and Chinese markets.
- Latest
- Trending
Bruker sees strong growth in Q2 2024, with strategic acquisitions boosting revenues despite challenges in biopharma and Chinese markets.
JPMorgan upgrades Bruker Corporation to Overweight, raising price target from $60 to $90, following strong Q4 performance and optimistic 2024 ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.